Virax Biolabs Group Ltd (NASDAQ:VRAX) currently has a daily average trading volume of 4.33M but it saw 67471024 shares traded in last market. With a market cap of 11.49M USD, the company’s current market price of $4.87 came falling about -0.41 while comparing to the previous closing price of $4.89. In past 52 weeks, the stock remained buoying in the range of price level as high as $9.00 and as low as $0.60. In the recent trading on the day, stock has struck highest price mark of $4.8 while lowest mark touched by it was $7.63.
Taking a look at 20-day trading activity of Virax Biolabs Group Ltd (VRAX) gives us an average price of $2.79, while its current price level is -45.89% below from 52-week high level whereas it is 711.67% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.85 while that of 200 days or SMA-200 reads an average of $1.33. A closer look into the stock’s movement over the week reveals that its volatility is standing at 31.34% during that period while stretching the period over a month that increases to 35.25%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 62.64 which implies that the stock is in neutral territory.
Over the week, VRAX’s stock price is moving -23.91% down while it is 289.60% when we observe its performance for the past one month. Year-to-date it is 233.56% up and over the past year, the stock is showing an upside performance of 34.27%.
The company is expected to be releasing its next quarterly report in September, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0.
Currently, Virax Biolabs Group Ltd’s total number of outstanding shares is 2.57M with 7.07% of that held by the insiders while 1.75% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -121.48% and return on equity (ROE) at -92.92%. Stock’s beta reads 1.86. Stock has a price to book (P/B) ratio of 2.34 while price to sale or P/S ratio amounts to 71.83. Its return on asset (ROA) is -88.04% on average.
